U.S. patent number RE35,500 [Application Number 08/389,269] was granted by the patent office on 1997-05-06 for direct radiolabeling of antibodies and other proteins with technetium or rhenium.
This patent grant is currently assigned to Aberlyn Capital Management Limited Partnership. Invention is credited to Buck A. Rhodes.
United States Patent |
RE35,500 |
Rhodes |
* May 6, 1997 |
Direct radiolabeling of antibodies and other proteins with
technetium or rhenium
Abstract
Proteins containing one or more disulfide bonds are radiolabeled
with radionuclides of technetium or rhenium for use in diagnosis
and treatment of a variety of pathologic conditions. Radiolabeling
is accomplished by partial reduction of the disulfide bonds of the
protein using Sn (II), or using other reducing agents followed by
the addition of Sn (II), removal of excess reducing agent and
reduction by-products, and addition of a specified amount of
pertechnetate or perrhenate reducing agent, such as stannous
tartrate, with the addition accomplished in such manner that
further reduction of the protein is limited. The resulting product
may be stored frozen or lyophilized, with radiolabeling
accomplished by the addition of pertechnetate or perrhenate
solution.
Inventors: |
Rhodes; Buck A. (Albuquerque,
NM) |
Assignee: |
Aberlyn Capital Management Limited
Partnership (Waltham, MA)
|
[*] Notice: |
The portion of the term of this patent
subsequent to January 7, 2009 has been disclaimed. |
Family
ID: |
27013516 |
Appl.
No.: |
08/389,269 |
Filed: |
February 16, 1995 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
391474 |
Aug 9, 1989 |
5078985 |
|
|
Reissue of: |
565275 |
Aug 8, 1990 |
05102990 |
Apr 7, 1992 |
|
|
Current U.S.
Class: |
424/1.49;
424/1.69; 530/391.5; 530/402 |
Current CPC
Class: |
A61K
51/08 (20130101); A61K 51/10 (20130101); C07K
5/081 (20130101); C07K 7/06 (20130101); C07K
14/52 (20130101); C07K 14/655 (20130101); C07K
14/78 (20130101); A61K 38/00 (20130101); A61K
2121/00 (20130101); A61K 2123/00 (20130101) |
Current International
Class: |
A61K
49/06 (20060101); A61K 49/08 (20060101); A61K
51/10 (20060101); A61K 51/08 (20060101); A61K
51/02 (20060101); C07K 5/083 (20060101); C07K
7/06 (20060101); C07K 7/00 (20060101); C07K
14/435 (20060101); C07K 14/52 (20060101); C07K
14/78 (20060101); C07K 5/00 (20060101); C07K
14/655 (20060101); A61K 38/00 (20060101); A61K
039/395 () |
Field of
Search: |
;424/1.49,1.69
;530/391.5,402 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
0237150 |
|
Jan 1987 |
|
EP |
|
0237150 |
|
Sep 1987 |
|
EP |
|
0271806 |
|
Dec 1987 |
|
EP |
|
0336678 |
|
Mar 1989 |
|
EP |
|
0336678 |
|
Apr 1989 |
|
EP |
|
8503231 |
|
Aug 1985 |
|
WO |
|
8704164 |
|
Jul 1987 |
|
WO |
|
8807382 |
|
Oct 1988 |
|
WO |
|
WO88/07382 |
|
Oct 1988 |
|
WO |
|
Other References
WC. Eckelman, "99 m Tc-Human Serum Albumin", Journal of Nuclear
Medicine, vol. 12, pp. 707-710 (1971). .
Baidoo, Kwamena E., et al., ".sup.99m Tc Labeling of Proteins:
Initial Evaluation of a Novel Diaminedithiol Bifunctional Chelating
Agent," Cancer Res. (Supp), vol. 50., pp. 799s-803s, (Feb. 1990).
.
Blok, D., et al., "A New Method for Protein Labeling with .sup.99m
Tc" Nucl. Med. Biol., vol. 6, No. 1, pp. 171-176 (1989). .
Breedveld, P., et al., "Imaging of Inflammatory Arthritis with
Technetium-99m-Labeled IgG", J. Nucl. Med., pp. 2017-2021 (1989).
.
Colombetti, L.G., et al., "A Rapid Method for Labeling IgG with
99m" J. Nucl. Med., vol. 20, p. 652 (1979). .
Eckelman, W.C. et al., "Three Approaches to Radiolabeling
Antibodies with 99mTc", Nucl. Med., Biol., vol. 16, No. 1, pp.
11-16 (1989). .
Kanellos, J., "Coupling of the 99m Technetium-Nitrido Group to
Monoclonal Antibody and Use of the Complexes for the Detection of
Tumors in Mice", JNCI, vol. 77, No. 2, pp. 431-439 (1986). .
Krejcarek, Gary E., et al., "Covalent Attachment of Chelating
Groups to Macromolecules," Biochem & Biophy. Res. Comm., vol.
77, No. 2, pp. 581-585, (1977). .
Lin, M.S., et al., "Use of Fe(II) or SN(II) Alone for Technetium
Labeling of Albumin", J. Nucl. Med., vol. 12, pp. 204-211 (1971).
.
Pak, K.Y., et al., "A Rapid and Efficient Method for Labeling IgG
Antibodies with Tc-99m and Comparison to Tc-99m FAB' Antibody
Fragments," Scientific Papers, Proceedings of the 36th Annual
Meeting, J. Nucl. Med., vol. 30, No. 5, p. 793 (No. 268), (1989)
Abstract. .
Rhodes, Buck A., et al., "Technetium-99m Labeling of Murine
Monoclonal Antibody Fragments," J. Nucl. Med., vol. 27, No. 5, pp.
685-693, (May 1986). .
Schwarz, A., et al., "A Novel Approach to Tc-99m-Labeled Monoclonal
Antibodies," Poster Sessions, Proceedings of 34th Ann. Mtg., J.
Nucl. Med., vol. 28, No. 4, p. 721 (No. 695), (Apr. 1987). .
Som, P., et al., "Radioimmunoimaging of Experimental Thrombi in
Dogs Using Technetium-99-m-Labeled Monoclonal Antibody Fragments
Reactive with Human Platelets," J. Nucl. Med., No. 8, pp.
1315-1320, (Aug. 1986). .
Stern, H.S., et al., "Technetium-99--Albumin" Book chapter
published by Johns Hopkins Medical Institutions, Baltimore MD pp.
359-375 (US Atomic Energy Comission) (1966). .
Wensel, Theodore G., et al., "`Bifunctional` Chelating Agents for
Binding Metal Ions to Proteins," S.W. Burchiel, and B.A. Rhodes,
Eds., Radioimmunoimaging and Radioimmunotherapy, pp. 185-196,
(1983). .
Wong, D.W., et al., "A Rapid Chemical Method of Labeling Human
Plasma Proteins with 99m Tc-Pertechnetate at pH 7.4", J. Applied
Radiation and Isotopes, vol. 29, pp. 251-253. .
Hosain, F., et al., "Radiation Does Estimation for Radioactive
Isotopes of Lead Labeled with Antibodies," Tract Submission Form,
Aug. 1988. .
Vuk-Pavlovic, S., et al., "Hapten-Induced Structural Changes in
Rabbit Immunoglobulin with Specifically Mercuriated
Inter-Heavy-Chain Disulfide," Biochenistry, vol. 18, No. 7, pp.
1125-1129, Apr. 3, 1979. .
Steiner, L., et al., "Mercury Derivatives of the Fab and Fc
Fragments of A Human Myeloma Protein," Biochemistry 10 Jul. 21,
1971 pp. 4725-4737. .
Pettit, W.A., et al., "Radiolabeling of Affinity-Purified Goat
Anti-Carcinoembryonic Antigen Immunoglobulin G with
Technicium-99m," Abstract, Cancer Research, Aug. 1980, pp.
3043-3045. .
Marek, M., et al., "Techniques For Direct Radiolabeling Of
Monoclonal Antobodies," Radiolabeled Blood Elements, J.
Martin-Comin, ed Plenum Press, NY 1994, pp. 207-220. .
Rhodes, B., et al., ".sup.99m Tc-Labeling and Acceptance Testing of
Radiolabeled Antobodies and Antobody Fragments," Tumor Imaging,
1979, pp. 111-123. .
Pettit, W.A., et al., "Improved Protein Labeling By Stannous
Tartrate Reduction of Pertechnetate," J. Nucl. Med., vol. 21, No.
1, 1980, pp. 59-62. .
Burchiel, S., et al., "Radiolabeling of Antibodies with
Technetium-99m," Radioimmunoimaging and Radiotherapy, 1983, pp.
207-222. .
Hansen, H., et al., "Preclinical Evaluation of an `Instant`
.sup.99m Tc-labeling Kit for Antobody Imaging," Cancer Research,
Sep. 8, 1988, pp. 794s-798s. .
Mather, S., et al., "Technetium-99m Labelled Hybrid
Receptor-Binding Peptides," J. Nucl. Bio. and Med., Sep. 1994, pp.
480-481. .
Baum, R., et al., "Initial Clinical Results with
Technetium-99m-Labeled LL2 Monoclonal Antibody Fragment in the
Radioimmunodetection of B-Cell Lymphomas," Cancer 73:896-9,
1994..
|
Primary Examiner: Chan; Christina Y.
Assistant Examiner: Gambel; Phillip
Attorney, Agent or Firm: Darby & Darby
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part application of U.S.
patent application Ser. No. 07/391,474, filed Aug. 9, 1989,
entitled Radiolabeling Antibodies and Other Proteins with
Technetium or Rhenium by Regulated Reduction, .Iadd.now U.S. Pat.
No. 5,032,237 .Iaddend.the teachings of which are incorporated
herein by reference.
Claims
What is claimed is:
1. A method of radiolabeling a protein containing one or more
monosulfide or disulfide bonds with a radionuclide to obtain stable
labeling, comprising the steps of:
a) incubating the protein containing monosulfide or disulfide bonds
with a first Sn (II) agent, the period of incubation being
sufficient to allow formation of Sn (II)-containing and
sulfur-containing complexes and formation of Sn (IV) reaction
by-products, while preventing excessive fragmentation of the
protein;
b) purifying the reduced protein to substantially remove
uncomplexed Sn agents and other impurities;
c) adding a second Sn (II) agent to the purified protein with Sn
(II)-containing and sulfur-containing complexes in a sufficient
mount to reduce the radionuclide yet not generate significant
radiochemical impurities, the radionuclide to be added in a
subsequent step; and
d) radiolabeling the purified protein with the Sn (II)-containing
and sulfur-containing complexes by adding the radionuclide, whereby
the Sn (II) agents reduce the radionuclide and the reduced
radionuclide forms radionuclide-containing and sulfur-containing
complexes.
2. The method of claim 1 wherein the source of the first Sn (II)
agent is present in a solution comprising alkali metal tartrate
having a pH of between approximately 5.0 and 6.0.
3. The method of claim 1 wherein the source of the second Sn (II)
agent is present in a solution comprising alkali metal tartrate
having a pH of between approximately 5.0 and 6.0.
4. The method of claim 1 wherein the source of the second Sn (II)
agent comprises at least one member selected from the group
consisting of stannous glucoheptonate, stannous gluconate and
stannous phosphonate.
5. The method of claim 1 wherein the protein comprises a member
selected from the group consisting of monoclonal antibodies,
monoclonal antibody fragments and polyclonal antibodies.
6. The method of claim 1 wherein following step c), and prior to
step d), the purified protein with Sn (II)-containing and
sulfur-containing complexes and second Sn (II) agent are frozen in
a vial, whereby the frozen purified protein with Sn (II)-containing
and sulfur-containing complexes and second Sn (II) agent can be
maintained for an indefinite period before radiolabeling in step d)
by the addition of the radionuclide to the vial.
7. The method of claim 1 wherein following step c), and prior to
step d), the purified protein with Sn (II)-containing and
sulfur-containing complexes and second Sn (II) agent are
lyophilized in a vial, whereby the lyophilized purified protein
with Sn (II)-containing and sulfur-containing complexes and second
Sn (II) agent can be maintained for an indefinite period before
radiolabeling in step d) by the addition of the radionuclide to the
vial.
8. The method of claim 1 wherein 85 percent or more of the
radionuclide is strongly bonded to the protein.
9. The method of claim 1 wherein the radionuclide comprises a
member selected from the group consisting of technetium and
rhenium.
10. The method of claim 9 wherein the radionuclide is
technetium-99m in the form of sodium pertechnetate.
11. A method of radiolabeling a protein containing one or more
monosulfide or disulfide bonds with a radionuclide to obtain stable
labeling, comprising the steps of:
a) incubating the protein containing monosulfide or disulfide bonds
with a Sn (II) agent, the period of incubation being sufficient to
allow formation of Sn (II)-containing and sulfur-containing
complexes and formation of Sn (IV) reaction by-products, while
preventing excessive fragmentation of the protein;
b) purifying the reduced protein to remove uncomplexed Sn agents
and other impurities yet retaining Sn (II) in a sufficient mount to
reduce the radionuclide and not generate significant radiochemical
impurities, the radionuclide to be added in a subsequent step;
and
c) radiolabeling the purified protein with the Sn (II)-containing
and sulfur-containing complexes by adding the radionuclide, whereby
the Sn (II) agent reduces the radionuclide and the reduced
radionuclide forms radionuclide-containing and sulfur-containing
complexes.
12. The method of claim 11 wherein the source of the first Sn (II)
agent is present in a solution comprising alkali metal tartrate
having a pH of between approximately 5.0 and 6.0.
13. The method of claim 11 wherein the protein comprises a member
selected from the group consisting of monoclonal antibodies,
monoclonal antibody fragments and polyclonal antibodies.
14. The method of claim 11 wherein following step b), and prior to
step c), the purified protein with Sn (II)-containing and
sulfur-containing complexes is frozen in a vial, whereby the frozen
purified protein with Sn (II)-containing and sulfur-containing
complexes can be maintained for an indefinite period before
radiolabeling in step c) by the addition of the radionuclide to the
vial.
15. The method of claim 11 wherein following step b), and prior to
step c), the purified protein with Sn (II)-containing and
sulfur-containing complexes is lyophilized in a vial, whereby the
lyophilized purified protein with Sn (II)-containing and
sulfur-containing complexes can be maintained for an indefinite
period before radiolabeling in step c) by the addition of the
radionuclide to the vial.
16. The method of claim 11 wherein 85 percent or more of the
radionuclide is strongly bonded to the protein.
17. The method of claim 11 wherein the radionuclide comprises a
member selected from the group consisting of technetium and
rhenium.
18. The method of claim 17 wherein the radionuclide is
technetium-99m in the form of sodium pertechnetate. .[.19. A method
of radiolabeling a protein containing one or more monosulfide or
disulfide bonds with a radionuclide to obtain stable labeling,
comprising the steps of:
a) incubating the protein containing monosulfide or disuifide bonds
with a first Sn (II) agent, the period of incubation being
sufficient to allow formation of Sn (II)-containing and
sulfur-containing complexes, while preventing excessive
fragmentation of the protein;
b) complexing the free Sn agents with a complexing agent so as not
to further reduce the protein, while retaining complexed Sn agents
for reducing the radionuclide, the radionuclide to be added in a
subsequent step; and
c) radiolabeling the protein with the Sn (II)-containing and
sulfur-containing complexes by adding the radionuclide, whereby the
completed Sn (II) agents reduce the radionuclide and the reduced
radionuclide forms radionuclide-containing and
sulfur-containing
complexes..]..[.20. The method of claim 19 wherein the complexing
agent is polyaminocarboxylic acid..]..[.21. The method of claim 19
wherein the polyaminocarboxylic acid comprises at least one member
selected from the group consisting of EDTA and DTPA..]..[.22. The
method of claim 19 wherein the source of the first Sn (II) agent is
present in a solution comprising alkali metal tartrate having a pH
of between approximately 5.0 and 6.0..]..[.23. The method of claim
19 wherein the protein comprises a member selected from the group
consisting of monoclonal antibodies, monoclonal antibody fragments
and polyclonal antibodies..]..[.24. The method of claim 19 wherein
following step b), and prior to step c), the free Sn complexes and
protein with Sn (II)-containing and sulfur-containing complexes are
frozen in a vial, whereby the frozen free Sn complexes and protein
with Sn (II)-containing and sulfur-containing complexes can be
maintained for an indefinite period before radiolabeling in step d)
by the addition of the radionuclide to the vial..]..[.25. The
method of claim 19 wherein following step b), and prior to step c),
the free Sn complexes and protein with Sn (II)-containing and
sulfur-containing complexes are lyophilized in a vial, whereby the
lyophilized free Sn complexes and protein with Sn (II)-containing
and sulfur-containing complexes can be maintained for an indefinite
period before radiolabeling in step d) by addition of the
radionuclide to the vial..]..[.26. The method of claim 19 wherein
85 percent or more of the radionuclide is strongly bonded to the
protein..]..[.27. The method of claim 19 wherein the radionuclide
comprises a member selected from the group consisting of technetium
and rhenium..]..[.28. The method of claim 27 wherein the
radionuclide is technetium-99m in the form of sodium
pertechnetate..]..[.29. The method of claim 19 wherein following
step b) a second Sn (II) agent is added to the combination of the
completing agent and protein with Sn (II)-containing and
sulfur-containing complexes in a sufficient mount to completely
reduce the radionuclide, whereby the reduced radionuclide forms
radionuclide-containing and sulfur-containing complexes..]..[.30.
The method of claim 29 wherein the source of the second Sn (II)
agent is present in a solution comprising alkali metal tartrate
having a pH of between approximately 5.0 and 6.0..]..[.31. The
method of claim 29 wherein the source of the second Sn (II) agent
comprises a member selected from the group consisting of stannous
glucoheptonate, stannous gluconate and stannous
phosphonate..]..[.32. The method of claim 29 wherein following the
addition of the second Sn (II) agent and prior to radiolabeling,
the free Sn complexes, second Sn (II) agent and protein with Sn
(II)-containing and sulfur-containing complexes are frozen in a
vial, whereby the frozen free Sn complexes, second Sn (II) agent
and protein with Sn (II)-containing and sulfur-containing complexes
can be maintained for an indefinite period before radiolabeling by
the
addition of the radionuclide to the vial..]..[.33. The method of
claim 29 wherein following the addition of the second Sn (II) agent
and prior to radiolabeling, the free Sn complexes, second Sn (II)
agent and protein with Sn (II)-containing and sulfur-containing
complexes are lyophilized in a vial, whereby the lyophilized free
Sn complexes, second Sn (II) agent and protein with Sn
(II)-containing and sulfur-containing complexes can be maintained
for an indefinite period before radiolabeling by the addition of
the radionuclide to the vial..]..[.34. The method of claim 29
wherein 85 percent or more of the radionuclide is strongly bonded
to the
protein..].35. A method of radiolabeling a protein containing
monosulfide or disulfide bonds with a radionuclide to obtain stable
labeling, comprising the steps of:
a) incubating the protein containing monosulfide or disulfide bonds
with a first reducing agent, the period of incubation being
sufficient to reduce available disulfide bonds to reactive sulfide
groups while preventing excessive fragmentation of the protein;
b) adding a source of first Sn (II) agent to the reduced protein to
allow formation of Sn (II)-containing and sulfur-containing
complexes;
c) purifying the reduced protein with Sn (II)-containing and
sulfur-containing complexes to substantially remove the first
reducing agent and impurities; and
d) radiolabeling the purified reduced protein with Sn
(II)-containing and sulfur-containing complexes by adding the
radionuclide, whereby the complexed Sn(II) agent reduces the
radionuclide and the reduced radionuclide and reduced protein form
radionuclide-containing and
sulfur-containing complexes. 36. The method of claim 35 wherein the
radionuclide comprises a member selected from the group consisting
of
technetium and rhenium. 37. The method of claim 35, wherein the
radionuclide is technetium-99m in the form of sodium pertechnetate.
38. The method of claim 35. wherein the first reducing agent
comprises at least one member selected from the group consisting of
2-mercaptoethanol; 1,4-dithiothreitol,
2,3-dihydroxybutane-1,4-dithiol, 2-aminoethanethiol
HCl; 2-mercaptoethylamine; thioglycolate; cyanide; and cysteine.
39. The method of claim 35, wherein the source of the first Sn (II)
agent of step b) is present in a solution comprising alkali metal
tartrate having a pH
of between approximately 5.0 and 6.0. 40. The method of claim 35
wherein the protein comprises a member selected from the group
consisting of monoclonal antibodies, monoclonal antibody fragments
and polyclonal
antibodies. 41. The method of claim 35 wherein following step c),
and prior to step d), the purified reduced protein with Sn
(II)-containing and sulfur-containing complexes are frozen in a
vial, whereby the purified reduced protein with Sn (II)-containing
and sulfur-containing complexes can be maintained for an indefinite
period before radiolabeling in step d)
by the addition of the radionuclide to the vial. 42. The method of
claim 35 wherein following step c), and prior to step d), the
purified reduced protein with Sn (II)-containing and
sulfur-containing complexes are lyophilized in a vial, whereby the
lyophilized purified reduced protein with Sn (II)-containing and
sulfur-containing complexes can be maintained for an indefinite
period before radiolabeling in step d) by the addition
of the radionuclide to the vial. 43. The method of claim 35 wherein
85 percent or more of the radionuclide is strongly bonded to the
protein.
The method of claim 35 wherein following step c) a second reducing
agent is added to the purified reduced protein with Sn
(II)-containing and sulfur-containing complexes in a sufficient
mount to completely reduce the radionuclide, whereby the reduced
radionuclide forms
radionuclide-containing and sulfur-containing complexes. 45. The
method of claim 44 wherein the second reducing agent comprises a
source of the Sn (II) agent present in a solution comprising alkali
metal tartrate having a
pH of between approximately 5.0 and 6.0. 46. The method of claim 44
wherein the second reducing agent comprises a member selected from
the group consisting of stannous glucoheptonate, stannous gluconate
and
stannous phosphonate. 47. The method of claim 44 wherein following
the addition of the second reducing agent and prior to
radiolabeling, the second reducing agent and purified reduced
protein with Sn (II)-containing and sulfur-containing complexes are
frozen in a vial, whereby the second reducing agent and purified
reduced protein with Sn (II)-containing and sulfur-containing
complexes can be maintained for an indefinite period
before radiolabeling by the addition of the radionuclide to the
vial. 48. The method of claim 44 wherein following the addition of
the second reducing agent and prior to radiolabeling, the second
reducing agent and purified reduced protein with Sn (II)-containing
and sulfur-containing complexes are lyophilized in a vial, whereby
the lyophilized second Sn reducing agent and purified reduced
protein with Sn (II)-containing and sulfur-containing complexes can
be maintained for an indefinite period
before radiolabeling by the addition of the radionuclide to the
vial. 49. The method of claim 44 wherein 85 percent or more of the
radionuclide
is strongly bonded to the protein. .Iadd.50. A method of
radiolabeling a whole antibody or F(ab').sub.2 antibody fragment
containing one or more disulfide bonds with a radionuclide to
obtain stable labeling, comprising the steps of:
a) incubating the antibody or fragment with a first Sn (II) agent,
the period of incubation being sufficient to reduce a portion of
the disulfide bonds and to allow formation of Sn (II)-containing
and sulfur-containing complexes, while preventing excessive
fragmentation of the antibody or fragment;
b) thereafter complexinh the free Sn agents with a subsequently
added polyaminocarboxylic acid complexing agent so as not to
further reduce the antibody or fragment, while retaining complexed
Sn agents for reducing radionuclide, the radionuclide to be added
in a subsequent step; and
c) radiolabeling the antibody or fragment with the Sn
(II)-containing and sulfur-containing complexes by adding the
radionuclide, whereby the complexed Sn (II) agents reduce the
radionuclide and the reduced radionuclide forms
radionuclide-containing and sulfur-containing complexes.
.Iaddend..Iadd.51. The method of claim 50 wherein the
polyaminocarboxylic acid comprises at least one member selected
from the group consisting of EDTA and DTPA. .Iaddend..Iadd.52. The
method of claim 50 wherein the source of the first Sn (II) agent is
present in a solution comprising alkali metal tartrate having a pH
of between approximately 5.0
and 6.0. .Iaddend..Iadd.53. The method of claim 50 wherein the
antibody or fragment is a member selected from the group consisting
of monoclonal antibodies, monoclonal F(ab').sub.2 fragments and
polyclonal antibodies. .Iaddend..Iadd.54. The method of claim 50
wherein following step b), and prior to step c), the free Sn
complexes and antibody or fragment with Sn(II)-containing and
sulfur-containing complexes are frozen in a vial, whereby the
frozen free Sn complexes and antibody or fragment with Sn
(II)-containing and sulfur-containing complexes can be maintained
for an indefinite period before radiolabeling in step d) by the
addition of the radionuclide to the vial. .Iaddend..Iadd.55. The
method of claim 50 wherein following step b), and prior to step c),
the free Sn complexes and antibody or fragment with Sn
(II)-containing and sulfur-containing complexes are lyophilized in
a vial, whereby the lyophilized free Sn complexes and antibody or
fragment with Sn (II)-containing and sulfur-containing complexes
can be maintained for an indefinite period before radiolabeling in
step d) by addition of the radionuclide to the vial.
.Iaddend..Iadd.56. The method of claim 50 wherein 85 percent or
more of the radionuclide is strongly bonded to the antibody or
fragment. .Iaddend..Iadd.57. The method of claim 50 wherein the
radionuclide comprises a member selected from the group consisting
of technetium and rhenium. .Iaddend..Iadd.58. The method of claim
50 wherein the radionuclide is technetium-99m in the form of sodium
pertechnetate.
.Iaddend..Iadd.59. The method of claim 50 wherein following step b)
a second Sn (II) agent is added to the combination of the
complexing agent and antibody or fragment with Sn (II)-containing
and sulfur-containing complexes in a sufficient amount to
completely reduce the radionuclide, whereby the reduced
radionuclide forms radionuclide-containing and sulfur-containing
complexes. .Iaddend..Iadd.60. The method of claim 59 wherein the
source of the second Sn (II) agent is present in a solution
comprising alkali metal tartrate having a pH of between
approximately 5.0 and 6.0. .Iaddend..Iadd.61. The method of claim
59 wherein the source of the second Sn (II) agent comprises a
member selected from the group consisting of stannous
glucoheptonate, stannous gluconate and stannous phosphonate.
.Iaddend..Iadd.62. The method of claim 59 wherein following the
addition of the second Sn (II) agent and prior to radiolabeling,
the free Sn complexes, second Sn (II) agent and antibody or
fragment with Sn (II)-containing and sulfur-containing complexes
are frozen in a vial, whereby the frozen free Sn complexes, second
Sn (II) agent and antibody or fragment with Sn (II)-containing and
sulfur-containing complexes can be maintained for an indefinite
period before radiolabeling by the addition
of the radionuclide to the vial. .Iaddend..Iadd.63. The method of
claim 59 wherein following the addition of the second Sn (II) agent
and prior to radiolabeling, the free Sn complexes, second Sn (II)
agent and antibody or fragment with Sn (II)-containing and
sulfur-containing complexes are lyophilized in a vial whereby the
lyophilized free Sn complexes, second Sn (II) agent and antibody or
fragment with Sn (II)-containing and sulfur-containing complexes
can be maintained for an indefinite period before radiolabeling by
the addition of the radionuclide to the vial. .Iaddend..Iadd.64.
The method of claim 59 wherein 85 percent or more the radionuclide
is strongly bonded to the antibody or fragment. .Iaddend.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention (Technical Field)
This invention relates to a method, composition and kit for
radiolabeling proteins, including antibodies, with radioisotopes of
technetium and rhenium such as tech- netium-99m.
2. Description of the Related Art Including Information Disclosed
under 37 C.F.R. Sections 1.97-1.99 (Background Art)
The use of radioisotopes to label proteins is well known. These
compositions can be used in assays, can be administered to the
human body to visualize or monitor functioning of various parts of
the body or to determine the presence and location of particular
antigens, antibodies, hormones and the like, and can be used in the
treatment of various disease states. A variety of radioisotopes,
including isotopes of iodine, technetium, indium, and rhenium have
been used. It is also well known that protein molecules can be
tagged or labeled with technetium-99m to form a diagnostic or
imaging agent.
Technetium-99m has been utilized to radiolabel proteins, chelating
agents, phosphonate bone scanning compositions and the like by a
technique which utilizes sodium pertechnetate wherein the
technetium initially is in the +7 state. Technetium-99m is
generally available only as sodium pertechnetate. The pertechnetate
must be contacted with a reducmg agent, such as stannous chloride,
in order to reduce the technetium to the +3, +4 or +5 oxidation
state in the presence of the protein, chelating agent or like
substance which is to be radiolabeled. The technetium must be
maintained in this reduced state in order to maintain the chemical
bond between the technetium molecule and the substrate being
radiolabeled. It is also necessary that the technetium be firmly
bound to the protein such that the reduced technetium is not
transferred to other molecules or other proteins present in the
assay, patient's blood or other media in which the radiolabeled
substance will be utilized.
Several different methods have been utilized to radio-label
proteins, particularly monoclonal antibodies, with technetium-99m.
The methods involve two general approaches. One approach is
indirect in which a bifunctional chelating agent is attached to the
protein via one functional group and the technetium-99m is attached
via the other functional, or chelating group. This method was
introduced by Krejcarek. G. E. and Tucker. K. L. ("Covalent
Attachment of Chelating Groups to Macromolecules," Biochemical and
Biophysical Research Communications Vol. 77, pp. 581-585, 1977) and
has been widely employed in many variations using a wide variety of
bifunctional chelating agents such as described in the review of
Wensel and Meares (Wensel, T. G., and Meares, C.F., "`Bifunctional`
Chelating Agents for Binding Metal Ions to Proteins,"
Radioimmunoimaging and Radioimmunotherapy, S. W. Burchiel and B. A.
Rhodes, eds., Elsevier Publishing Co., New York, pp. 185-196,
1983). Other methods are disclosed by Hnatowich, D. J., U.S. Pat.
Nos. 4,668,503 and 4,479,930, by Haber, E., and Khaw, B. A., U.S.
Pat. No. 4,421,735, by Fritzberg, A. R., and Kasina, S., U.S. Pat.
No. 4,670,545 and by Baidoo, K. E., et al, ".sup.99m Tc Labeling of
Proteins: Irtitial Evaluation of Novel Diaminedithiol Bifunctional
Chelating Agent," Cancer Res (Supp), Vol. 50, pp. 799s-803s, 1990.
The bifunctional chelate methods all present significant
limitations, including the complexity of the radiolabeling
procedure, the time required to accomplish radiolabeling, and the
introduction and presence of substances which may affect the
protein.
The other general approach is direct labeling. Although several
direct methods have been reported, the fast direct method capable
of providing a sufficiently strong bond between the protein and the
technetium-99m for in vivo applications was the direct or
pretinning method described in U.S. Pat. No. 4,424,200, entitled
Method for Radiolabeling Proteins with Technetium-99m, to
Crockford, D. R., and Rhodes, B. A. In this method, a single
reduction solution, consisting of stannous [Sn (II)] chloride with
tartrate and phthalate salts, is used. This solution serves to (1)
reduce the protein, thereby exposing reactive sulfide groups, (2)
protect the reactive sulfide groups of the reduced protein to
prevent reformation of disulfide bonds, (3) reduce sodium
pertechnetate, and (4) complex the reduced Tc-99m and transfer it
to the sulfide binding sites of the reduced protein. With this
method, many proteins can be successfully radiolabeled with
technetium-99m. Several investigators have reported on the use of
this method (Rhodes, B. A., et al, "Technetium-99m Labeling of
Murine Monoclonal Antibody Fragments," Journal of Nuclear Medicine,
Vol. 27, pp. 685-693, 1986: Some, P., et al, "Radioimmunoimaging of
Experimental Thrombi in Dogs Using Technetium-99m-Labeled
Monoclonal Antibody Fragments Reactive with Human Platelets,"
Journal of Nuclear Medicine, Vol. 27, No. 8, pp. 1315-1320,
1986).
Other early direct labeling methods were reported, but did not
yield a stable Tc-protein bond. The reason for the instability of
the Tc-protein bond in prior methods (Stern, H. S., et al.,
Radioactive Pharmaceuticals, U.S. Atomic Energy Commission (1966),
Textbook, Chapter 19, pp. 359-375; Lin, M. S., et al., "Use of Fe
(II) or Sn (II) Alone for Technetium Labeling of Albumin," Journal
of Nuclear Medicine, Vol. 12, No. 5, pps. 204-211, 1970; Eckelman,
W. C., et al., .sup.99m Tc-Human Serum Albumin," Journal of Nuclear
Medicine, Vol. 12, No. 11, pp. 707-710, 1971; Wong, D. W., et al.,
"A Rapid Chemical Method of Labeling Human Plasma Proteins with
.sup.99m Tc-Pertechnetate at pH 7.4," International Journal of
Applied Radiation and Isotopes, Vol. 29, pp. 251-253, 1978;
Colombetti, L. G., et al., "A Rapid Method for Labeling IgG with
99m-Tc," Journal of Nuclear Medicine, Vol. 20, p. 652, 1979;
Rhodes, B. A., U.S. Pat. No. 4,305,922, Labeling Proteins with
99m-Tc by Ligand Exchange, was that the protein had not been
reduced to provide reactive sulfide groups which are necessary for
the formation of strong bonds between the protein and the reduced
radionuclide.
Subsequently, a number of methods have been reported which employ
variations on the method of U.S. Pat. No. 4,424,200. These
variations generally involve one or more of the following: (1)
Disulfide reducing agents other than Sn (II), such as
2-mercaptoethanol, dithiothreitol and their analogs, are used to
reduce the protein; (2) reactive sulfide group protecting agents
other than Sn (II), such as Zn (II), are employed; (3)
pertechnetate reducing agents other than Sn (II), such as
dithiothreitol, are used; and (4) complexing agents other than
tartrate, such as phosphonates, are used to bind the reduced
technetium and transfer it to the sulfide groups of the
protein.
These methods have generally not resulted in any improvement over
the method of U.S. Pat. No. 4,424,200. None of the methods
disclosed yield results comparable to those achieved with the
method, composition and kit disclosed herein.
Schwarz, A., and Steinstruaber, A., "A Novel Approach to
Tc-99m-Labeled Monoclonal Antibodies," Journal of Nuclear Medicine,
Vol. 28, p. 721, 1987, and Bremer, K. H., et al., European Patent
Office Application No. 0 271 806 A2 filed Dec. 8, 1987), reduce the
disulfide groups of the protein with monothiols, such as
2-mercaptoethanol or 2-mercaptoethylamine. Sn (II) is used to
reduce the pertechnetate and the reduced technetium is complexed
with phosphonates or pyrophosphates. This method requires two or
more vials and multiple steps to achieve radiolabeling. The
phosphonates used can give rise to radiocolloid impurities in the
final product. In addition, the chemicals used to reduce the
disulfide groups, such as 2-mercaptoethanol, are potentially
toxic.
Reno, J. W., et al., U.S. Pat. No. 4,877,686 Radionuclide Antibody
Coupling and European Patent Office Application No. 0 237 150
(filed Jan. 19, 1987), used dithiothreitol (DTT) to reduce the
disulfide groups of the protein, then protect the reactive sulfides
with Zn (II) or other sulfhydryl group derivatizing reagents. They
use tartrate salts to complex and transfer the reduced
radionuclide. This method uses potentially toxic chemicals, such as
dithiothreitol, to reduce the antibody. It also requires multiple
steps to radiolabel the protein.
Pak, K. Y., et al, "A Rapid and Efficient Method for Labeling IgG
Antibodies with Tc-99m and Comparison to Tc-99m Fab' Antibody
Fragments," Journal of Nuclear Medicine, vol. 30, p. 793, 1989, and
Patent Cooperation Treaty International Patent Application No. WO
88/07382 (filed Apr. 1, 1988), used dithiothreitol to reduce the
antibodies. Tartrate or glucoheptonate salts and their analogs are
added to complex and transfer the reduced radionuclides. This
method also uses potentially toxic chemicals, and requires multiple
steps to radiolabel.
Shochat, D., et al., European Patent Office Application No. 0 336
678 (filed Apr. 3, 1989) use conventional disulfide reducing
agents, such as cysteine, dithiothreitol, 2-mercaptoethanol,
dithionite or the like. They claim that the pretinning method of
U.S. Pat. No. 4,424,200 does not work well, indicating that some of
the radiometal is bound to sites which are comparatively labile in
the presence of blood or other bodily fluids or tissues. They give
a single example in the application, preparation of
Tc-99m-anti-CEA-Fab', which example appears to be exactly that of
the '200 patent. The use of Sn (II) to reduce sodium pertechnetate
is well known in the prior art, and is disclosed in the '200 patent
and other references.
The advantage of the Sn (II) method of reducing disulfides of
proteins over other methods is that the Sn (II) both reduces the
bond and complexes with the sulfide formed by the reduction to
protect the sulfide from reverting to unreactive disulfide. When
organic reducing agents such as DTT are used to reduce the
disulfide groups of the protein, the reducing agent must be removed
before sulfide protecting groups are added, otherwise the
protecting groups will react, usually by formation of a
precipitate, with the reducing agent. If the reducing agent is
first removed to avoid this reaction between it and the sulfide
protecting agent, then the reduced protein is left for a period of
time in which the reactive sulfide groups can reform unreactive
disulfide bonds. The Sn (II) reduction method, described in this
invention, is new in that it permits simultaneous reduction and
complexing of disulfides.
Other methods of direct labeling have also been reported which
differ chemically from the four-step process described above. Paik,
C. H. et al., U.S. Pat. No. 4,652,440, Method of Stably
Radiolabeling Antibodies with Technetium and Rhenium, label
proteins by Sn (II) reduction in the presence of a strong chelating
agent, DTPA, which competes for the reduced radionuclide. Only
strongly bonded Tc-99m labeling of the protein occurs probably by
binding to native free sulfhydryl groups of the protein. However,
considerable amounts of Tc-99m-DTPA are also formed and must be
removed before the labeled protein can be used. This method lacks
the first step of reducing the disulfide bonds needed to achieve
high yields of strongly bonded radionuclide.
Sundrehagen, E., Patent Cooperation Treaty International Patent
Application No. WO 85/03231 (filed Jan. 18, 1985), used gentisic
acid to stabilize the low concentrations of Sn (II) used to reduce
the pertechnetate. This method is useful in minimizing
radiochemical impurities such as radiocolloids and oxidized
radionuclide. This method lacks the first step of reducing the
disulfide bonds needed to achieve high yields of strongly bonded
radionuclide.
Lees, R. S., U.S. Pat. No. 4,647,445, Radiolabelled Lipoproteins
and Method of Making Same uses dithionite at pH 8 to 9 to reduce
both pertechnetate and lipoproteins simultaneously. This method
requires that the labeled product be purified by column
chromatography to remove radionuclidic impurities prior to use.
Breedveld, F. C., et al., "Imaging of Inflammatory Arthritis with
Technetittm-99m-Labeled IgG," Journal of Nuclear Medicine, Vol. 30,
No. 12, pp. 2017-2021, 1989, first reduce pertechnetate with
hydrochloric acid and then extract, transfer, and reduce the
radionuclide to dryness. The protein is added to the vessel
containing the dry, reduced radionuclide. Labeling is achieved
during a 60 minute incubation at 40.degree. C. This method requires
extensive preprocessing of the radionuclide and is thus not readily
applied to an instant kit process for labeling and formulating a
drug.
McKenzie, I., et al., "Coupling of the .sup.99m Technetium-Nitrido
Group to Monoclonal Antibody and Use of the Complexes for the
Detection of Tumors in Mice," Journal of the National Cancer
Institute, Vol. 77, pp. 431-439, 1986, and Patent Cooperation
Treaty Patent Application No. WO 87/04164 (filed Jan. 6, 1987),
reduce antibodies to provide free sulfhydryl group binding sites or
introduce free sulfhydryl groups binding sites and label the sites
with .sup.99m TcN(Cl).sub.4 --. The product requires purification
by gel chromatography to remove radiochemical impurities prior to
use.
All previous methods are limited because they fail to provide a
one-step labeling kit and method which yields, within 15 minutes,
an injectable product free of significant radiochemical impurities
and a product in which the radionuclide is quantitatively and
strongly bonded to the protein without altering immunoreactivity
when the protein being labeled is an antibody. In addition, many
previous methods employ potentially toxic chemicals. Although the
pretinning method of Crockford and Rhodes was able to provide a
rapid, one-step labeling process yielding approximately 85% of the
radionuclide strongly bonded to the protein, the radiochemical
purity has not been high enough for clinical application of all
monoclonal antibodies, and some products require final purification
prior to patient administration. In the present invention, both the
optimum conditions for reducing the protein and the optimum
conditions for reducing the radionuclide can be achieved while
retaining the convenience of one-step labeling. This is achieved by
adding steps to the manufacturing process. The protein is reduced
with Sn (II) as in the original pretinning method described by
Crockford and Rhodes. After reduction is completed, the reduced
protein is put through a purification or complexing step to remove
excess reducing agent and reaction by-products such as stannic
chloride or other Sn (IV) agents. Alternately, an organic reducing
agent is used to reduce the protein, the organic reducing agent and
reaction products then removed, and Sn (II) is added to form a Sn
(II) and sulfur containing protein complex. A Sn (II) radionuclide
reducing agent is added to the reduced protein solution in
concentrations and with complexing agents which are optimum for
subsequent radiolabeling. The reduced protein together with the
radionuclide reducing solution are aliquoted, frozen and optionally
lyophilized for storage until needed for radiolabeling.
Another alternative is to reduce the antibody using the pretinning
method of Crockford and Rhodes disclosed in the '200 patent at
optimal concentration of reagents for reducing the protein and
forming the Sn (II) and sulfur containing protein complex, and then
diluting this solution with reagents to achieve conditions which
are optimal for reducing the radionuclide and causing it to
transfer to the protein.
SUMMARY OF THE INVENTION
DISCLOSURE OF THE INVENTION
In accordance with the present invention, a method is provided for
radiolabeling proteins with technetium or rhenium in which a
reducing agent is used to reduce the disulfide bonds in the
protein; excess reducing agent, reaction by-products and any
impurities are removed; and, an optimum low concentration and
limited mount of pertechnetate or perrhenate reducing agent added
to reduce the sodium pertechnetate or perrhenate and facilitate the
rapid labeling of the reduced protein by ligand exchange.
In the preferred embodiment, a protein substrate to be radiolabeled
is admixed with a solution of Sn (II) chloride composition having a
pH of between about 4.5 and about 8.5, and preferably about pH 5.6,
the solution further comprising a mixture of sodium potassium
tartrate and potassium hydrogen phthalate, the pH adjusted to
approximately 5.6.+-.0.05 using sodium hydroxide, and the resulting
solution purged of oxygen. Alternatively, the solution may include
other salts such as sodium chloride, sodium acetate, gentisic acid,
or stannous fluoride. The Sn (II) salt solution is added to the
protein in an oxygen free environment, and the protein and Sn (II)
salt solution allowed to incubate for several hours (usually
twenty-one hours) in the absence of oxygen and at room temperature.
Alternately higher or lower incubation temperatures may be used
with a corresponding inverse change in the incubation time, such
that if the incubation temperature is increased, the incubation
time is decreased, and vice versa. For certain proteins, such as
some monoclonal antibodies or fragments thereof, the reaction time
may be shortened to less than 21 hours to prevent excessive
fragmentation of the antibody protein, and can be further reduced
if the protein already contains reactive sulfide groups.
Alternatively, the protein may be reduced more rapdly by incubating
it with a disulfide group reducing agent, such as dithiothreitol
(DTT) in the ratio of 10 mg of DTT per 5 mg of protein per ml of
aqueous solution at pH 7.5 to 9.0 for 30 minutes at room
temperature. The reducing agent is removed, by purification by any
means. This is followed by adding dilute HCl to reduce the pH to
5.6.+-.0.05, and then adding Sn (II) tartrate at pH
5.6.+-.0.05.
Following incubation, the protein and Sn (II) salt solution is
either frozen to stop the reduction reaction, or is immediately
purified by size exclusion chromatography using an appropriate gel
in a column equilibrated with saline. The protein and buffered Sn
(II) salt solulion is loaded into the column, and eluted using
saline, with the molecular weights of the eluant monitored and
relevant fractions collected. If necessary, a small amount of Sn
(II) solution is added. The fractions corresponding to the protein
to be radiolabeled are collected and pooled, and concentrated by
ultrafiltration. Alternatively, the protein may be purified by any
other suitable method including such methods as dialysis,
ultrafiltration, precipitation, preparative high performance liquid
chromatography, affinity chromatography, other forms of
chromatography or preparative isoelectric focusing. The resulting
protein, substantially free of excess Sn (II) salt solution, Sn
(IV) salts, contaminants or proteins of molecular weight other than
the protein to be radiolabeled, can then be frozen in an oxygen
free vial.
To the oxygen free vial containing the frozen purified, reduced and
Sn (II) complexed protein, a solution capable of reducing sodium
pertechnetate or perrhenate in saline solution is added in a manner
to prevent immediate admixing of the two solution. A pure tin
pellet can also be added to each vial. The resulting combination is
prepared as layers of frozen solutions or is otherwise prepared
without allowing any reaction between the frozen, purified, and
reduced protein and the solution for reducing the sodium
pertechnetate or perrhenate. A carrier protein may also be added to
protect against radiolysis of the purified and reduced protein, and
to prevent adhesion of the purified and reduced protein to
surfaces, such as the vial wall. A layer of carrier protein, such
as non-reduced human serum albumin or another inert diluent such as
inositol or another inert sugar, or an amino acid, such as glycine,
is added, and the layer is frozen or otherwise prepared without
allowing any admixture with the other solutions until use. Oxygen
is excluded from the vial containing the two unmixed solutions. The
vial is stored frozen or it is lyophilized and stored for
subsequent reconstitution when radiolabeling is desired. The
solution for reducing the sodium pertechnetate or perrhenate
comprises stannous chloride and a mixture of sodium potassium
tartrate and potassium hydrogen phthalate, the pH adjusted to
approximately 5.6.+-.0.05 using sodium hydroxide, and the resulting
solution purged of oxygen. In practice, frequently the same Sn (II)
salt solution can be used to reduce both the protein and the sodium
pertechnetate or perrhenate; however, the amount or concentration
of Sn (II) salts used to reduce sodium pertechnetate or perrhenate
is substantially less than the amount of concentration used to
reduce the protein. Alternatively, the solution used for reducing
sodium pertechnetate or perrhenate can be composed of any substance
which effectively reduces sodium pertechnetate or perrhenate and
does not alter the protein to be radiolabeled, such as stannous
tanrate, stannous phosphonate, stannous gluconate, stannous
glucoheptonate, or other substances capable of reducing
pertechnetate or perrhenate. The stannous chloride and all such
other stannous compounds are referred to in the specification and
claims as Sn (II). No more of the pertechnetate or perrhenate
reducing solution than is required to reduce the sodium
pertechnetate or perrhenate is used. This is done to prevent
possible degradation of the protein, primarily by further cleavage
of disulfide bonds due to the action of the radionuclide reducing
reagent.
Solid, highly pure metallic tin may be added to the vial, generally
at or after freezing, and in the form of a non-oxidized tin pellet.
The addition of metallic tin prevents oxidation loss during storage
and reconstitution.
The resulting frozen or lyophilized combination of purified,
reduced, Sn (II) and sulfur containing completed protein and the
radionuclide reducing solution, together with the tin pellet,
carrier protein and other inert diluents, are admixed with sodium
pertechnetate-Tc-99m or perrhenate solution while avoiding the
introduction of oxygen. The admixture is then incubated for a
period (usually fifteen minutes) at room temperature to allow for
the reduction of the technetium or rhenium and its binding to the
reduced and Sn (II) complexed protein. The admixture may be
stabilized by the addition of human serum albumin or other similar
protein in normal saline, if a carrier protein was not included in
the original vial.
This thus provides a method for radiolabeling proteins containing
reactive sulfide groups with radionuclides of technetium or rhenium
to obtain stable labeling, by incubating the protein with a first
reducing agent to partially reduce the disulfide bonds, purifying
the reduced and Sn (II) complexed protein to remove excess first
reducing agent sad all impurities, and adding only so much of
second reducing agent as is necessary to reduce pertechnetate or
perrhenate. A preferred first reducing agent is a source of Sn (II)
in a solution composed of a mixture of an alkali metal biphthalate
and an alkali metal tartrate having a pH of between about 5.0 and
6.0. The first reducing agent may also be 2-mercaptoethanol,
1,4-dithiothreitol, 2,3-dihydroxybutane-1,4-dithiol,
2-aminoethanethiol HCl, 2-mercaptoethylamine, thioglycolate,
cyanide, cysteine or other substances capable of reducing disulfide
bonds, with Sn (II) then added to form an intermediate Sn (II) and
sulfur containing complex. A preferred second reducing agent is a
source of Sn (II) in a solution composed of a mixture of an alkali
metal biphthalate and an alkali metal tartrate having a pH of
preferably between about 5.0 and 6.0. The second reducing agent may
also be Sn (II) tanrate, Sn (II) gluconate, Sn (II) glucoheptonate,
Sn (II) phosphonate, dithionite or other substances capable of
reducing pertechnetate or perrhenate. Following the purification of
the protein combination, the purified protein combination can be
frozen, the second reducing agent added, and the second reducing
agent immediately frozen so that no chemical reaction occurs
between the purified protein combination and second reducing agent
prior to thawing for use. It is also possible, following the
freezing of the protein combination and the second reducing agent,
to lyophilize the composition. At or subsequent to the addition of
the second reducing agent, solid, non-oxidized metallic tin can be
added to the combination of the protein combination and the second
reducing agent. Purification may be accomplished by passage of the
protein combination through a size exclusion chromatography column,
or by methods such as use of a desalting column, dialysis,
ultrafiltration, precipitation, preparative high performance liquid
chromatography, affinity chromatography, or preparative isoelectric
focusing. Optimal results are obtained when the concentration of
the protein in the protein combination and second reducing agent is
at least 1 milligram per milliliter of solution, and the volume of
the protein combination and second reducing agent is at least 2
milliliters.
This invention provides for a composition suitable for use in
preparing a protein having a stable label of a radionuclide of
technetium or rhenium, which composition comprises a protein which
has been reduced so that a radionuclide and sulfur containing
complex can be formed, so much of a Sn (II)-containing reducing
compound for pertechnetate or perthchute as will reduce the
pertechnetate or perrhenate without further reduction of the
protein, and optionally pure, non-oxidized metallic tin. The source
of pure, non-oxidized metallic tin may be a tin pellet. The
composition may be made using a reduced antibody or antibody
fragment as the reduced protein. An inert career substance may also
be added to the composition, such as an inert sugar or non-reduced
inert protein. The composition may be lyophilized, preferably
buffered at a pH of 4 to 6.
A kit is also provided which includes the frozen or lyophilized
combination of purified and Sn (II) and sulfur containing complexed
protein and the radionuclide reducing solution in a single oxygen
purged vial, together with stabilizing agents, if required, ready
for radiolabeling.
Proteins with either monosulfide or disulfide bonds can be
radiolabeled with radionuclides such as technetium or rhenium by
incubation with a first Sn (II) agent, or other reducing agent,
which may be as described above. The period of incubation must be
sufficient to allow formation of Sn (II) and sulfur containing
complexes. As a result of the formation of the complexes, Sn (IV)
reaction by-products, such as stannic chloride, and other
impurities, such as protein fragments or polymers, may be formed. A
purification step is then employed to substantially remove Sn (IV)
and other impurities. A second Sn (II) agent may then be added to
the protein containing Sn (II) and sulfur containing complexes, in
an amount sufficient to reduce the radionuclide. The radiolabeling
is then accomplished by adding the radiolabel, whereby the second
Sn (II) agent reduces the radionuclide and the reduced radionuclide
forms radionuclide and sulfur containing complexes in the
protein.
Radiolabeling may also be accomplished by omitting the step of
addition of a second Sn (II) agent, in which case the residual
first Sn (II) agent reduces the radionuclide and the reduced
radionuclide forms radionuclide and sulfur containing complexes in
the protein. This may be accomplished by diluting the reaction
mixture after the protein containing Sn (II) and sulfur containing
complexes have been formed.
These methods are particularly applicable to technetium-99m in the
form of sodium pertechnetate. Both the first and second Sn (II)
agents are optimally present in a solution containing alkali metal
tartrate at a pH of between 5.0 and 6.0. The second Sn (II) agent
can also consist of substances such as stannous glucoheptonate,
stannous gluconate, stannous phosphonate, dithionate, or other
substances capable of reducing radionuclides.
These methods are particularly applicable to monoclonal antibodies,
monoclonal antibody fragments and polyclonal antibodies. These
methods can be used to make product, which product on radiolabeling
with technetium or rhenium by introduction of sodium pertechnetate
or perrhenate and an incubation period, is further characterized by
having 85% or more of the technetium or rhenium strongly bonded to
the protein. Further, when product is made using monoclonal
antibodies or monoclonal antibody fragments, the immunoreactivity
of the product is substantially the same as the immunoreactivity of
the antibody prior to incubation with the first Sn (II) agent. The
product may be lyophilized, and does not require filtration or
purification prior to patient in vivo administration.
Proteins with either monosulfide or disulfide bonds may also be
radiolabeled with radionuclides such as technetium or rhenium using
a modification of the method above. The protein is incubated with a
first Sn (II) agent, which may be as described above. The period of
incubation must be sufficient to allow formation of Sn (II) and
sulfur containing complexes. As a result of the formation of the
complexes, Sn (IV) reaction by-products and other impurities may be
formed. Sn (IV) reaction by-products can then be complexed with a
polyaminocarboxylic acid, such as ethylenediaminetetraacetic acid
(EDTA) or diethylenetriaminopentaacetic acid (DTPA). Radiolabeling
is accomplished by adding the radionuclide, whereby the residual
first Sn (II) agent reduces the radionuclide and the reduced
radionuclide forms radionuclide and sulfur containing complexes in
the protein.
Radiolabeling may optimally be performed by the addition of a
second Sn (II) agent, to facilitate reduction of the radionuclide,
polyaminocarboxylic acid.
The methods using polyaminocarboxylic acid are particularly
applicable to technetium-99m in the form of sodium pertechnetate.
Both the first and second Sn (II) agents are optimally present in a
solution containing alkali metal tartrate at a pH of between 5.0
and 6.0. The second Sn (II) agent can also consist of substances
such as stannous glucoheptonate, stannous gluconate, stannous
phosphonate, or other substances capable of reducing
radionuclides.
The methods using polyaminocarboxylic acid are particularly
applicable to monoclonal antibodies, monoclonal antibody fragments
and polyclonal antibodies. These methods can be used to make
product, which product on radiolabeling with technetium by
introduction of sodium pertechnetate and an incubation period, is
further characterized by having 85% or more of the technetium
strongly bonded to the protein. Further, when product is made using
monoclonal antibodies of monoclonal antibody fragments, the
immunoreactivity of the product is substantially the same as the
immunoreactivity of the antibody prior to incubation with the first
Sn (II) agent. The product may be lyophilized, and does not require
filtration or purification prior to patient in vivo
administration.
All the foregoing methods result in a proteinaceous composition in
which is found a Sn (II) and sulfur containing complex, comprising
reactive sulfide groups complexed with Sn (II), and which
composition is suitable for radiolabeling with radionuclides such
as technetium and rhenium. The composition may also comprise a Sn
(II) reducing agent in an mount sufficient to reduce the
radionuclide, and may also contain a completing agent, preferably a
polyaminocarboxylic acid such as EDTA or DTPA. The protein may be a
monoclonal antibody, monoclonal antibody fragment or polyclonal
antibody, and may be made into a product. The product may be
lyophilized. On radiolabeling with technetium by introduction of
sodium pertchnetate and an incubation period, the product is
further characterized by having 85% or more the technetium strongly
bonded to the protein. It is also further characterized by
requiring an incubation period of fifteen minutes or less.
Accordingly, it is an object of the present invention to provide a
method for direct labeling of proteins with technetium or rhenium,
which method will eliminate undesirably fragments or otherwise
degraded protein components from the final product.
It is a further object of the present invention to provide a method
which results in increased radiolabeling efficiencies utilizing
technetium or rhenium as the radioisotope.
It is a further object of the present invention to provide a method
to radiolabel antibodies or antibody fragments without loss of
affinity of the antibodies or antibody fragments due to the
radiolabeling process.
It is a further object of the present invention to provide a method
for radiolabeling proteins with technetium or rhenium which does
not use potentially toxic or injurious chemicals or substances in
the method.
Another object of the present invention is to provide a method and
kit which permits radiolabeling to be accomplished by the end user
using a single vial, containing both reduced antibody and stannous
ions, and further containing a means to maintain low quantities of
stannous ions while protecting against oxidation loss, which method
requires only a single step to accomplish radiolabeling, being the
introduction of sodium pertechnetate.
Other objects, advantages and novel features, and further scope of
applicability of the present invention will be set forth in part in
the detailed description to follow and in part will become apparent
to those skilled in the art upon examination of the following, or
may be learned by practice of the invention. The objects and
advantages of the invention may be realized and attained by means
of the instrumentalities and combinations particularly pointed out
in the appended claims.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE
INVENTION
(BEST MODES FOR CARRYING OUT THE INVENTION)
Any protein, chelating agent or other substrate which contains one
or more monosulfide or disulfide bonds which can be reduced can be
radiolabeled in accordance with this invention. Representative
suitable substrates include human serum albumin, fibrinogen,
urokinase, gamma globulin, glycoproteins, other proteins and
antibodies, or antibody fragments, of any species, and including
both polyclonal and monoclonal antibodies made by any means, as
well as chimeric and genetically engineered antibodies, and
antibody fragments of all of the foregoing. This includes
immunoglobulins of any class, such as IgG, IgM, IgA, IgD, or IgE,
of any species origin, including human beings, chimeric antibodies
or or hybrid antibodies with dual or multiple antigen or epitope
specifities, and fragments of all the foregoing, including
F(ab').sub.2, F(ab).sub.2, Fab', Fab and other fragments, including
hybrid fragments, and further includes any immunoglobulin or any
natural, synthetic or genetically engineered protein that
functionally acts like an antibody by binding to a specific antigen
to form a complex. The term "antibody" or "antibodies", and the
phrase "monoclonal antibody component", as used throughout the
specification and claims is intended to include all such antibodies
and antibody fragments.
The present invention, through inclusion of a purification step,
and concomitant removal of excess reducing reagents, presents a
number of significant advantages. By removal of all species of
reduced protein other than the protein to be radiolabeled,
including smaller or larger molecular weight species, competition
for reduced Tc-99m is eliminated. This results in significantly
higher radiolabeling yields. By keeping the total amount of
stannous and stannic ions in the pertechnetate or perrhenate
reducing solution as low as possible, the formation of additional
reduced protein species is minimized. It generally takes far fewer
stannous ions to reduce pertechnetate or perrhenate than to reduce
the disulfide bonds in proteins, thereby allowing reduction of
disulfide bonds in the protein to be radiolabeled, which additional
reduction could result in protein species other than the protein to
be radiolabeled.
The present invention also presents significant advantages because
it requires only one step to accomplish radiolabeling by the end
user, the addition of sodium, pertechnetate or perrhenate and the
concomitant incubation thereof. This significant simplification is
possible because both the stannous ions and the reduced antibody
are frozen, together with a carrier protein and other inert
diluents, and optionally lyophilized, in the same vial. The
addition of the tin pellet, or other source of purified and
non-oxidized metallic tin, further preserves the low concentration
of stannous ions and helps prevent loss of radiolabel due to
oxidation dung storage or reconstitution.
The invention is further illustrated by the following non-limiting
examples.
EXAMPLE I
A Sn (II) reducing solution was made composed of stannous chloride
in a tartrate-phthalate solution. Stannous chloride was prepared by
dissolving stannous chloride crystals in concentrated hydrochloric
acid at 0.5M, yielding approximately 94.8 mg of stannous chloride
per ml. This solution was then stored in sealed and nitrogen purged
vials until used. Alternate sources for stannous chloride can be
used, including use of a non-oxidized solid tin pellet contacted
with concentrated hydrochloric acid.
A tartrate-phthalate solution of a mixture of sodium potassium
tartrate and potassium hydrogen phthalate was prepared. 0.282 g of
sodium potassium tartrate was dissolved in 100 ml of distilled
water, and to this was added 0.817 g potassium hydrogen phthalate.
The pH was adjusted to approximately 5.0, using 10N sodium
hydroxide, and was then adjusted to 5.6.+-.0.05 using 1N sodium
hydroxide. The resulting solution was stirred and purged of oxygen
by bubbling an inert gas, such as nitrogen, helium or the like,
through the substance. The Sn (II) reducing solution was made by
measuring a portion of the purged tartrate-phthalate solution into
a flask, and slowly adding thereto a volume of the stannous
chloride, It is preferable if a stir bar or similar mechanism is
used to insure mixture of the stannous chloride as it is added to
the solution. Approximately one volume of stannous chloride to 100
volumes of buffer was used. The pH was continuously monitored, and
once the stannous chloride was added, the pH was adjusted to
approximately 5.0, using 10N sodium hydroxide, and was then
adjusted to 5.6.+-.0.05 using 1N sodium hydroxide.
All steps are undertaken in an oxygen free environment, and may be
done while bubbling an inert gas through the solution. The
resulting solution is purged of oxygen by bubbling an inert gas,
such as nitrogen, helium or the like, through the substance.
Alternately, the antibody reducing solution can be made using other
disulfide reducing agents such as 2-mercaptoethanol 1,4
dithiothreitol, 2,3 dihydroxybutane-1,4-dithiol, 2-aminoethanethiol
HCl, 2-mercaptoethylamine, thioglycolate, cyanide, cysteine, or
other disulfide splitting reagents.
The protein to be reduced is placed in a nitrogen purged, sealed
vial. If monoclonal antibody or fragments thereof are to be
labeled, of a minimum of 0.1 mg, and preferably at least 2 mg, of
monoclonal antibody or fragments is used, at a concentration of 1
mg or more per ml, preferably 1.7 mg/ml. The monoclonal antibody,
fragments or other protein may be diluted in normal saline, or
concentrated by ultrafiltration, as may be necessary. To the
protein, Sn (II) reducing solution is added, in the approximate
ratio of 3 volumes of protein to 2 volumes of Sn (II) reducing
solution. The vial containing the protein and Sn (II) reducing
solution is then allowed to incubate, preferably in an oxygen free
environment, such as a container filled with nitrogen or another
inert gas. The vial is allowed to incubate at room temperature for
a period sufficient to allow reduction of the disulfide bonds in
the protein. Generally, incubation for between one and twenty-four
hours at room temperature is adequate, with incubation for
twenty-one hours at room temperature being preferred for most whole
immunoglobulins. If the temperature is increased, the incubation
time is decresed, and conversely, incubation at lower temperatures
requires correspondingly longer incubation times. Incubation is
terminated by freezing the admixture of protein and Sn (II)
reducing solution by dilution or by proceeding immediately to
purification.
When other reducing agents are used, such as 2-metcaptoethanol,
1,4-dithiothreitol, 2,3-dihydroxybutane-1,4-dithiol,
2-aminoethanethiol HCl, 2-mercaptoethylamine, thioglycolate,
cyanide, cysteine, or other disulfide splitting reagents, the
incubation time must be adjusted for the specific reducing agent
being used. Generally, a shorter incubation time is required. After
the reducing solution is removed, Sn (II) salt is added to form a
Sn (II) and sulfur containing complex, and thus preserve the
reduced disulfide groups during subsequent purification steps. The
purification steps undertaken with these reducing agents must
remove substantially all of the reducing agent.
The admixture of protein and Sn (II) reducing or other reducing
solution is purified, preferably by size exclusion chromatography.
A column is packed with an appropriate gel, such as Sephacryl-200
gel (Pharmacia, Piscataway, N.J.) for use with low molecular weight
monoclonal antibody F(ab').sub.2 fragments. The column is
equilibrated with an appropriate elution buffer, such as gentisate
buffered saline. The admixture of protein and reducing solution is
applied to the column and fractionated, using the elution buffer. A
fraction profile is generated using an ultraviolet detector or
similar device, and the fractions containing the resulting protein
to be radiolabeled are collected and pooled. The resulting reduced
protein is concentrated, if necessary, preferably to a
concentration of 1.7 mg/ml. Concentration can be accomplished by
ultrafiltration. The resulting concentrate can also be dialyzed
against normal saline to remove any residual Sn (IV) salts or other
residual reducing agent.
Alternately, the admixture of Sn (II) and sulfur conraining
complexed protein and Sn (II) or other reducing solution may be
purified by passage of the admixture through a desalting column,
collecting the reduced protein and discarding the Sn (IV) salts and
excess reducing reagents. The resulting eluant can be concentrated
and dialyzed as required. This method will remove excess Sn (II)
solution. Sn (IV) reaction by-product and other reducing reagents,
but will not necessarily remove other impurities. such as smaller
fragments of the protein resulting from over reduction of the
disulfide bonds in the protein or aggregation of reduced proteins.
These small fragments or large aggregates, in the case of
monoclonal antibodies, may not be immunoreactive, or may have a
biodistribution different than that of the desired protein,
necessitating their removal from the final product.
Alternately, the admixture of reduced protein and Sn (II) or other
reducing solution may also be purified by other means, including
dialysis, ultrafiltration, precipitation, preparative high
performance liquid chromatography, affinity chromatography, other
forms of chromatography, preparative isoelectric focusing, and
other purification means common to the art.
The purified, reduced and Sn (II) complexed protein is then purged
of oxygen, preferably by bubbling an inert gas such as nitrogen
through the solution, and can be frozen in oxygen-purged vials, To
each vial containing frozen protein solution, pertechnetate
reducing solution is added, and the contents either immediately
frozen or lyophilized, so that no reaction takes place between the
frozen protein solution and the pertechnetate reducing solution. A
non-oxidized tin pellet may also be added to the vial, which tin
pellet will replace trace mounts of Sn (II) and help to stabilize
the low concentration of stannous ions in the pertechnetate
reducing solution, and to help prevent losses of radiolabel due to
reoxidation dunng storage of the radiolabeled product. The
pertechnetate reducing solution can be made as the Sn (II) reducing
solution was made, except that approximately one volume of stannous
chloride at 0.5M is added to approximately 5,000 volumes of
tartrate-phthalate solution, resulting in a pertechnetate reducing
solution of approximately 0.1 millimolar. Approximately one volume
of pertechnetate reducing solution is added to two volumes of
purified, reduced and Sn (II) complexed protein. Optimally, the
protein solution is at a concentration of approximately 1.7 mg/ml,
and to each 1.32 ml of the purified, reduced and Sn (II) complexed
protein solution, approximately 0.68 ml of pertechnetate reducing
solution is added.
Alternately, the pertechnetate reducing solution can be made using
Sn (II) glucoheptonate, Sn (II) tartrate, Sn (II) phosphonate,
dithionite and other commonly used Tc-99m radiopharmaceutical
kits.
The pertechnetate reducing solution can also be used to reduce
perrhenate. The discussion of pertechnetate and pertechnetate
compounds throughout the specification is also applicable to
perrhenate and perrhenate compounds. Likewise, the discussion
throughout the specification of technetium and its compounds is
appliable to rhenium and its compounds.
To radiolabel, the desired activity of sodium pertechnetate-Tc-99m
is added and admixed, and the admixture allowed to incubate for a
period, generally approximately fifteen minutes. This step is
conducted while avoiding or minimizing the introduction of
atmospheric oxygen. If desired, the resultant radiolabeled protein
can be stabilized by the addition of 1% human serum albumin in
normal saline or other suitable protective protein.
The source of technetium-99m is conventionally obtained as sodium
pertechnetate-Tc-99m from a 99Mo/99mTc generator. Any source of
pharmaceutically acceptable technetium-99m may be utilized in the
present invention.
Alternatively other radioisotopes of technetium and isotopes of
rhenium such as Re-186 and Re-188 may be used. When perrhenate
rather than pertechnetate is reduced, usually a higher temperature
and a longer radiolabeling time are required to carry the reaction
to completion.
EXAMPLE II
This example illustrates the process of this invention for labeling
immunoglobulin G (IgG). IgG is obtained from animals such as sheep,
goats, mice or humans. Sodium Pertechnetate-Tc-99m U.S.P. is
obtained from any commercial source.
A Sn (II) disulfide bond reducing agent was prepared by adding 0.2
ml of 0.5M stannous chloride in concentrated HCl (12M) to 20 ml of
40 mM potassium biphthalate and 10 mM sodium tartrate solution (pH
of 5.6). The stannous chloride was prepared by adding the
concentrated hydrochloric acid to non-oxidized pellets of
SnCl.sub.2 having a surface free of dull stannous oxide. The pH of
the resultant reducing solution then was brought up to 5.6.+-.0.05,
by adding 10M NaOH to a pH of 5.5, and adding 1M NaOH to adjust to
the final pH.
An IgG preparation was made by diluting 0.25 ml of Immune Globulin
(Human), U.S.P., Cutter Biological, which contained 15-18% protein
stabilized with 0.21-0.32M glycine, with 7.25 ml of Sterile Water
for Injection, U.S.P., and filtering through a 0.22 micron filter.
5 ml of the Sn (II) reducing solution was mixed with 7.5 ml of the
IgG preparation. The vial containing the admixed solutions was
sealed and flushed with N.sub.2 gas to remove oxygen. This admixed
solution was stored for 21 hours at room temperature in the dark to
allow for the partial reduction of disulfide bonds to form what is
referred to subsequently as reduced protein. After the 21 hour
incubation the contents of the vial was passed through a PD-10
desalting column (Pharmacia LKB Biotechnology, Piscataway, N.J.);
the protein containing fraction was collected and the remaining
eluate, which contained the Sn (II), Sn (IV) and other salts, was
discarded. The reduced and Sn (II) complexed protein fraction was
concentrated by ultrafiltration to a concentration of 1.7 mg/ml.
0.5 mg aliquots of reduced and Sn (II) complexed protein were
placed in sealed, N.sub.2 gas filled serum vials and frozen. A Sn
(II) pertechnetate reducing solution was made of 0.5 ml of 0.1 mM
SnCl.sub.2 in 40 mM potassium biphthalate/10 mM sodium tartrate at
a pH of 5.6. The Sn (II) pertechnetate reducing solution was added
without allowing the reduced antibody solution to thaw, and this
solution was also frozen. A sterile, 3 mm diameter tin metal shot
was added, the vial flushed with N.sub.2 and stored at -20.degree.
C. until needed for radiolabeling.
To radiolabel the gamma giobulin preparation with Tc-99m, 1.0 ml of
Sodium Pertechnetate-Tc-99m, U.S.P., containing 2.5 mCi of
radioactivity, was added to the vial, and the vial and contents
brought to room temperature, mixed and allowed to stand for 15
minutes. Thin layer chromatographic analysis of the product
revealed that 99.6% of the radioactivity was protein bound. High
performance liquid chromatography, using both UV and radioisotope
detectors, showed that the Tc-99m elution paralleled the protein
elution profile.
EXAMPLE III
This example illustrates the process of this invention for labeling
monoclonal murine antibodies of IgG and IgM classes. The antibody
was obtained from murine ascites or bioreactor fluid, purified to
greater than 95%, and prepared at concentrations of greater than 1
mg/ml in 0.9% NaCl solution.
A Sn (II) reducing solution was prepared as in Example II. Two
whole antibody preparations were tested; B72.3, an IgG murine
antibody, and anti-SSEA-1, an IgM murine antibody. Each antibody
preparation was at a protein concentration of 1.7 mg/ml. To each ml
of purified protein solution was added 0.66 ml of Sn (II) reducing
solution. The admixed solutions were incubated and passed through a
PD-10 column as in Example II. The reduced protein fraction was
concentrated by ultrafiltration to a concentration of 2 mg/ml.
Aliquots of reduced protein, containing from 0.5 to 2.0 mg protein,
were placed in sealed, N.sub.2 gas filled serum vials and
frozen.
A pertechnetate reducing solution was prepared by dissolving 50 mg
of gentisic acid, 0.375 .mu.g SnCl.sub.2 and 975 .mu.g of sodium
potassium tartrate in 50 ml of distilled water which had previously
been deoxygenated by bubbling N.sub.2 gas through it for two to
three minutes. The pH was adjusted to 7.0 by addition of very
dilute (0.05N) NaOH. Equal volumes of this solution were layered
over the frozen, reduced and Sn (II) complexed protein solution and
this solution frozen. A sterile, 3 mm diameter tin metal shot was
added, the vial flushed with N.sub.2 and stored at -20.degree. C.
until needed for radiolabeling.
To radiolabel the IgG or IgM preparations with Tc-99m. 1.0 ml of
Sodium Pertechnetate-Tc-99m, U.S.P., containing 2.5 mCi of
radioactivity, was added to each vial, and the vial and contents
brought to room temperature, mixed and allowed to stand for 15
minutes. Thin layer chromatographic analysis of the products
revealed that 90.0% to 96.5% of the radioactivity was protein
bound. High performance liquid chromatography (HPLC), using both UV
and radioisotope detectors, showed that the Tc-99m elution
paralleled the protein elution profile. No non-protein bound
radioactivity was found by HPLC analysis.
EXAMPLE IV
This example illustrates the process of this invention for labeling
F(ab').sub.2 fragment of monoclonal antibody. This example also
shows that the composition of the radiolabeled product varies with
the method and type of disulfide reducing reagent used. This
example also shows that the current method is superior to the
original direct labeling method of Crockford and Rhodes, U.S. Pat.
No. 4,424,200 entitled "METHOD FOR RADIOLABELING PROTEINS WITH
TECHNETIUM-99M", for this particular monoclonal antibody fragment.
The F(ab').sub.2 fragment was obtained by pepsin digestion of
murine monoclonal antibody followed by chromatographic purification
which separated the F(ab').sub.2 fragments from other material
found in the pepsin digest with greater than 95% purity.
The monoclonal antibody fragment used in this example was obtained
from Sorin Biotechnica, Italy. It was a murine anti-CEA
F(ab').sub.2 which previous experimentation had shown very poor
radiolabeling with Tc-99m using the pretinning method.
Four different radiolabeling procedures were employed; one used the
original pretinning method described in U.S. Pat. No. 4,424,200,
and the other three procedures used methods taught in this
invention. The four procedures can be summarized as follows:
1. The original pretinning method described in U.S. Pat. No.
4,424,200, in which a Sn (II) reducing solution was prepared as
described in Example II, but no purification step was employed, and
no pertechnetate reducing solution was added.
2. The method of this invention using Sn (II) reducing solution to
reduce disulfide bonds in the antibody fragment, as described in
Example II, including a purification step using a PD-10 desalting
column, and a pertechnetate reducing solution composed of stannous
salt with a tin pellet.
3. The method of this invention using 2-mercaptoethanol to reduce
disulfide bonds in the antibody fragment. A 5% solution of
2-mercaptoethanol was prepared in 0.1M phosphate buffer at pH 8.0.
One ml of this solution was added to 1 mg of the lyophilized
antibody fragment protein and mixed to dissolve. After 1 hour
incubation at room temperature, 1.6 ml of saline was added and the
partially reduced protein separated from the other components in
the solution by passage through a PD-10 desalting column. The
protein was concentrated by ultrafiltration to 1.7 mg/ml. A
pertechnetate reducing solution composed of stannous salt with a
tin pellet, as described in Example II, was then applied.
4. The method of this invention using dithiothreitol to reduce
disulfide bonds in the antibody fragment. 15.4 mg of
dl-dithiothreitol (DTT) was dissolved in 10 ml of a solution of 50
mM tris and 1 mM EDTA at pH 8.0. For each mg of lyophilized protein
to be reduced, 0.33 ml of the reducing solution was added with
mixing to dissolve the protein. The reduction mixture was allowed
to react at 37.degree. C. for one hour. The partially reduced
protein was purified by size exclusion column chromatography with
collection of the protein fraction corresponding to the molecular
weight of the original F(ab').sub.2 antibody fragment. The
chromatographically purified fragment was concentrated to 1.7 mg/ml
in 0.9% saline by ultrafiltration. A pertechnetate reducing
solution composed of stannous salt with a tin pellet, as described
in Example II, was then applied.
For each of the four preparations, the frozen and vialed antibody
fragment was radiolabeled and tested as described in Example II.
The results of the four different procedures utilizing the same
antibody fragment are listed in Table 1.
Table 1 shows that this specific F(ab').sub.2 murine monoclonal
antibody fragment effectively fails to radiolabel using the
original pretinning method taught in U.S. Pat. No. 4,424,200, in
which there is no purification step and no addition of limited
mounts of pertechnetate reducing solution, yet effectively
radiolabels using methods of this invention, particularly when an
agent other than Sn (II) was used to reduce the disulfide bonds.
The same pertechnetate reducing agent, here Sn (II), was used in
each procedure. Conditions were not optimized during the procedure
to obtain greater than 85% binding. The purpose of the comparison
was to show how the binding can be grossly improved by using the
process of invention.
TABLE I
__________________________________________________________________________
COMPARISON OF RESULTS USING DIFFERENT METHODS FOR PARTIAL REDUCTION
OF THE DISULFIDE BONDS OF ANTI-CEA F(ab').sub.2 Disulfide Reduction
Method Results
__________________________________________________________________________
Original pretinning U.S. Pat. No. 4-9% of the Tc-9m bound to
F(ab').sub.2 ; 45-53% 4,424,200 method bound to smaller fragments.
This invention using Sn (II) 18-29% of the Tc-99m bound to
F(ab').sub.2 ; 51-76% bound to smaller fragments. This invention
using 79% of the Tc-99m bound to F(ab').sub.2 ; none
2-mercaptoethanol bound to smaller fragments. This invention using
DTT 74% of the Tc-99m bound to F(ab').sub.2 ; none bound to smaller
fragments
__________________________________________________________________________
EXAMPLE V
This example illustrates the process of this invention for labeling
a monoclonal antibody which cannot be satisfactorily labeled by the
original direct or pretinning method, or by other equivalent direct
labeling methods. The reason for the failure of the previous direct
methods with certain monoclonal antibodies is that during the
reduction of the antibody either fragmentation or aggregation of
the antibody occurs which results in protein species of altered
molecular weight. An example of this is an anti-CEA murine
monoclonal IgG provided by Sorin Biomedia, Italy. When this
antibody is reduced with Sn (II) salts, small mounts of fragments
are formed which label preferentially with the reduced Tc-99m. When
this antibody is reduced with dithiothreitol or 2-mercaptoethanol,
dimers and polymers of reduced IgG are formed which label with
Tc-99m. By the method of this invention, the antibody, after the
disulfide bond reduction step, is purified by passage through a
size exclusion chromatograph column. The column eluate
corresponding only to the molecular weight of the original antibody
was separated from both the smaller or larger protein species. A
quantity of pertechnetate reducing solution sufficient to reduce
the sodium pertechnetate but not to further reduce disulfide bonds
in the antibody was added, and the antibody radiolabeled. The
resulting Tc-99m labeled protein was of the correct molecular
weight and free of the smaller or large molecular weight
contaminants.
EXAMPLE VI
This example illustrates the use of purification and EDTA to obtain
higher HPLC yields.
Four aliquots of a chimeric IgG monoclonal antibody were reduced
with a Sn (II) reducing agent as in Example II. Two aliquots were
purified by passage through a PD-10 column, followed by addition of
Sn (II) pertechnetate reducing solution. The remaining two aliquots
were not purified, and no additional Sn (II) pertechnetate reducing
solution was added. To one of each of the two pairs of aliquots,
ethylenediaminetetraacetic acid (EDTA) was added prior to
radiolabeling.
Quantitative radiochemical purity was determined by HPLC yield. In
this method, the percent of strongly bonded Tc-99m is determined as
the percent of Tc-99m recovered in HPLC size exclusion
chromatography of the total Tc-99m injected multiplied by the
percent of Tc-99m under the IgM protein peak. Weakly bonded Tc-99m
is almost completely transferred and bound to the HPLC column, with
unreduced Tc-99m elutes, but not with the protein peak. This method
thus provides a measure of strongly bonded Tc-99m.
TABLE 2 ______________________________________ COMPARISON OF
RESULTS USING EDTA TO PARTIALLY BIND IMPURITIES HPLC Reduction
Method Yield ______________________________________ 1. SN (II)
reduction, no purification 52% 2. SN (II) reduction, no
purification, EDTA 78% 3. SN (II) reduction, PD-10 desalting
column, 96% SN (II) pertechnetate reducing solution 4. SN (II)
reduction, PD-10 desalting column, 97% SN (II) pertechnetate
reducing solution, EDTA ______________________________________
EXAMPLE VII
This example illustrates the formation of reactive sulfide groups
on reduction of disulfide bonds by Sn (II) and by dithiothreitol
(DTT). Murine monoclonal IgM antibody was labeled with I-125 using
the Iodobead method. Aliquots were incubated with Sn (II) reducing
solution made as in Example II; the aliquots were removed at
different time intervals, up to 21 hours, and passed through a
PD-10 column to stop the reduction reaction. Aliquots were also
incubated with DTT. Sodium chloride was used as a control. The
PD-10 columns were eluted with nitrogen purged saline to prevent
reoxidation of reactive sulfide groups. One portion of each aliquot
was used for measurement of free reactive sulfide groups and the
other portion was used for TC-99m labeling and the measurement of
the percent of strongly bonded Tc-99m.
Reactive sulfide group formation was determined by relative binding
of the I-125 labeled antibody to Thio Avidgel F (Bioprobe, Justin,
Calif.). Thio Avidgel F binds proteins which have free sulfhydryl
or reactive sulfide groups: if such groups are formed during
incubation with reducing agents, then the percent antibody binding
should be proportional to reactive sulfide, groups. Tc-99m labeling
was accomplished by using a Sn (II) pertechnetate reducing
solution, prepared as in Example II, to which was added human serum
albumin and inositol. The percent strongly bonded Tc-99m was
determined by HPLC yield as described in Example VI.
TABLE 3 ______________________________________ SULFHYDRYL GROUP
CORRELATION TO STRONGLY BONDED Tc-99m Reducing Incubation Time
Percent Binding Agent (Hours) To Thiogel HPLC Yield
______________________________________ NaCl NA 10% 5.1% Sn (II) 1
14% 20.9% SN (II) 21 23% 46.7% DTT 1 62% 57.8%
______________________________________
EXAMPLE VIII
This example illustrates that the process of this invention, using
the Sn (II) reducing agent of Example II followed by passage
through a PD-10 column, does not affect the immunoreactivity of
monoclonal antibodies. F(ab').sub.2 antibody specific for myosin
was spiked with I-125 labeled polyclonal immune globulin. A portion
was reduced as described and passed through a PD-10 column.
Aliquots of both the reduced F(ab').sub.2 and unreduced
F(ab').sub.2 were then adjusted to yield the same concentration
using the I-125 labeled polyclonal immune globulin as the standard.
ELISA was performed against purified heavy chain myosin antigen
with both aliquots using decreasing concentrations of the
F(ab').sub.2 antibody. The affinity constants were calculated at
one-half plateau maximum absorbance, and were found to be
identical.
The preceding examples can be repeated with similar success by
substituting the generically or specifically described reactants
and/or operating conditions of this invention for those used in the
preceding examples. In particular, other proteins, chelating agents
or substrates which contain monosulfide or disulfide bonds which
can be reduced may be used in place of IgG, IgM and F(ab').sub.2
monoclonal antibody; other reducing agents can be used to reduce
the disulfide bonds in the substance to be radiolabeled; other
purification methods can be used to remove the reducing agent;
other pertechnetate reducing agents can be used to reduce the
sodium pertechnetate; and isotopes of rhenium can be used in
addition to isotopes of technetium. The foregoing are merely
illustrative, and other equivalent embodiments are possible and
contemplated.
Although the invention has been described with reference to these
preferred embodiments, other embodiments can achieve the same
results. Variations and modifications of the present invention will
be obvious to those skilled in the art and it is intended to cover
in the appended claims all such modifications and equivalents.
* * * * *